2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Breast
2
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Refractory/Relapse Neuroblastoma
1
Papillomavirus Infections
1
Osteoporosis
1
Neuroendocrine Tumors
1
Neoplasms, Squamous Cell
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, B-Cell
1
Kidney Neoplasms
1
Inflammatory Bowel Diseases
1
Infertility
1
Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma
1
Hodgkin Disease
1
High Grade Cervical Intraepithelial Neoplasia
1
Esophageal Neoplasms
1
Burkitt Lymphoma
1
Interventions
Trastuzumab
628
Paclitaxel
577
Cyclophosphamide
555
Docetaxel
485
Capecitabine
401
Letrozole
376
Fulvestrant
327
Doxorubicin
294
Carboplatin
279
Tamoxifen
275
Anastrozole
243
exemestane
228
Radiotherapy
218
Epirubicin
211
Bevacizumab
196
palbociclib
189
pertuzumab
186
Vinorelbine
167
Lapatinib
167
Gemcitabine
166
pembrolizumab
162
Surveys and Questionnaires
138
Exercise
136
Magnetic Resonance Spectroscopy
123
Fluorouracil
119
Blood Specimen Collection
118
eribulin
117
Albumin-Bound Paclitaxel
117
Drug Therapy
111
130-nm albumin-bound paclitaxel
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Biological Products
×
Clear all
NCT05843539
2025-07-22
CAPONE
University of Lorraine
Completed
100 enrolled
NCT04382352
2023-03-24
B002-101
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1
Completed
23 enrolled